Effectiveness of prophylactic central compartment neck dissection following hemithyroidectomy in papillary thyroid cancer: a meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
2132 patients who met the inclusion criteria: six retrospective cohort studies and one randomized controlled trial.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
pCCND did not demonstrate significant efficacy in improving oncological outcomes for low-risk patients with cN0 PTC. Therefore, for patients with low-risk cN0 PTC, thyroid surgeons should make reasonable and individualized decisions regarding the extent of surgical removal.
[INTRODUCTION] In this study, we aimed to assess the effect of prophylactic central compartment neck dissection (pCCND) in conjunction with hemithyroidectomy (HT) for clinically low-risk node-negative
- OR 0.67
- 연구 설계 meta-analysis
APA
Zhao P, Liang LL, et al. (2025). Effectiveness of prophylactic central compartment neck dissection following hemithyroidectomy in papillary thyroid cancer: a meta-analysis.. ANZ journal of surgery, 95(1-2), 26-33. https://doi.org/10.1111/ans.19210
MLA
Zhao P, et al.. "Effectiveness of prophylactic central compartment neck dissection following hemithyroidectomy in papillary thyroid cancer: a meta-analysis.." ANZ journal of surgery, vol. 95, no. 1-2, 2025, pp. 26-33.
PMID
39435979
Abstract
[INTRODUCTION] In this study, we aimed to assess the effect of prophylactic central compartment neck dissection (pCCND) in conjunction with hemithyroidectomy (HT) for clinically low-risk node-negative (cN0) papillary thyroid carcinoma (PTC).
[METHODS] A thorough literature search was performed utilizing PubMed and EMBASE for articles published until October 2023. Subsequently, a meta-analysis was performed on studies involving patients with cN0 PTC, with postoperative locoregional recurrence (LRR) and survival data, treated with HT + pCCND or HT. The study was registered with PROSPERO (CRD42024560962).
[RESULTS] We included seven studies in this meta-analysis, including 2132 patients who met the inclusion criteria: six retrospective cohort studies and one randomized controlled trial. The HT + pCCND group consisted of 1090 cases, and the HT group had 1042 cases. The LRR rates after HT with or without pCCND were similar (3.58% vs. 4.51%; odds ratio (OR) = 0.65; 95% confidence interval (CI) = 0.41-1.03). Five of the seven studies provided prognostic and survival data, particularly the log hazard ratio (log HR) of disease-free survival (DFS) between the two groups. There was also no significant difference in terms of DFS between the HT + pCCND and HT groups (OR = 0.67; 95% CI = 0.42-1.07).
[CONCLUSIONS] There was no significant difference in LRR and DFS between the HT + pCCND and HT groups. pCCND did not demonstrate significant efficacy in improving oncological outcomes for low-risk patients with cN0 PTC. Therefore, for patients with low-risk cN0 PTC, thyroid surgeons should make reasonable and individualized decisions regarding the extent of surgical removal.
[METHODS] A thorough literature search was performed utilizing PubMed and EMBASE for articles published until October 2023. Subsequently, a meta-analysis was performed on studies involving patients with cN0 PTC, with postoperative locoregional recurrence (LRR) and survival data, treated with HT + pCCND or HT. The study was registered with PROSPERO (CRD42024560962).
[RESULTS] We included seven studies in this meta-analysis, including 2132 patients who met the inclusion criteria: six retrospective cohort studies and one randomized controlled trial. The HT + pCCND group consisted of 1090 cases, and the HT group had 1042 cases. The LRR rates after HT with or without pCCND were similar (3.58% vs. 4.51%; odds ratio (OR) = 0.65; 95% confidence interval (CI) = 0.41-1.03). Five of the seven studies provided prognostic and survival data, particularly the log hazard ratio (log HR) of disease-free survival (DFS) between the two groups. There was also no significant difference in terms of DFS between the HT + pCCND and HT groups (OR = 0.67; 95% CI = 0.42-1.07).
[CONCLUSIONS] There was no significant difference in LRR and DFS between the HT + pCCND and HT groups. pCCND did not demonstrate significant efficacy in improving oncological outcomes for low-risk patients with cN0 PTC. Therefore, for patients with low-risk cN0 PTC, thyroid surgeons should make reasonable and individualized decisions regarding the extent of surgical removal.
MeSH Terms
Humans; Neck Dissection; Thyroidectomy; Thyroid Cancer, Papillary; Thyroid Neoplasms; Neoplasm Recurrence, Local; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- The oncogene c-MYC: An orchestrator of the tumor microenvironment and drug sensitivity in small cell lung cancer.
- A self-amplifying cuproptosis nanomedicine to overcome immunosuppression by blocking tumor-derived exosomes for enhancing lung cancer immunotherapy.
- SPP1⁺ macrophage-FADS1⁺ tumor cell crosstalk via the PDGFB-PDGFRB axis drives liver metastasis in colorectal cancer.
- Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design.
- Functional regulatory roles of HNF1B in promoting cell proliferation, migration, invasion and fate decision of hepatocellular carcinoma.